Print this article
- 12/19/2016

Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps®

Pharma Horizon

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Horizon Pharma plc (“Horizon”)  have entered into a five-year distribution agreement for Ravicti® (glycerol phenylbutyrate) in European countries, including United Kingdom, Germany, France, Italy and Spain and for Ammonaps® (sodium phenylbutryate) in the same European countries and certain Middle Eastern countries.  Under the agreement, Sobi will have exclusive marketing, sales and distribution rights for the two medicines in the territory until 31 December 2021. Horizon has the ability to terminate the agreement after two years subject to certain pre-defined termination fees.  Sobi currently distributes Ravicti in certain Middle Eastern countries and Ammonaps in certain European and Middle Eastern countries.

Ravicti and Ammonaps are authorised by the European Commission and are indicated for the treatment of Urea Cycle Disorders (UCD).

“We are happy to build on our successful relationship with Horizon Pharma to support providing treatment to people living with UCDs”, says Alan Raffensperger, Chief Operating Officer of Sobi and continues:  “This distribution agreement will allow us to leverage our existing expertise and extensive experience within the area of UCDs.  Our main focus now will turn to implementing patient access activities with the objective to launch Ravicti in Europe during 2017.”

“Sobi has been a trusted partner in Europe and the Middle East for the last three years,” says Francoise de Craecker, group vice president and general manager, EMEA, orphan business unit, Horizon Pharma plc.  “We believe that Sobi’s current distribution of Ammonaps uniquely qualifies it to effectively provide Ravicti to people living with UCDs in European markets.”